期刊文献+

恶性胸腔积液的肿瘤微环境特征与治疗进展

Characteristics of the tumor microenvironment and therapeutic progress in malignant pleural effusion
原文传递
导出
摘要 恶性胸腔积液(malignant pleural effusion, MPE)可继发于多种晚期恶性肿瘤。尽管全身抗肿瘤治疗对原发肿瘤治疗有效, 但仍有部分患者MPE控制不佳。肿瘤细胞、免疫细胞、间质细胞相互作用以及肿瘤相关血管异常增殖构建了MPE免疫抑制微环境, 促进肿瘤细胞异常增殖和MPE的形成。随着对肿瘤微环境的深入研究, 胸腔内局部应用免疫检查点抑制剂、免疫细胞及细胞因子和基因介导的细胞毒等免疫疗法可有效改善免疫抑制的肿瘤微环境, 抑制MPE的形成。本文将阐述MPE的肿瘤微环境特征及相应的治疗新进展。 Malignant pleural effusion(MPE)can be secondary to various advanced malignant tumors.Although systemic anti tumor therapy may be effective in primary tumors,it cannot reduce the accumulation of MPE in proportion of the patients.The interaction of tumor cells,immune cells,and mesenchymal cells,as well as the abnormal proliferation of tumor-associated blood vessels,together create an immunosuppressive microenvironment for MPE,which promotes the abnormal proliferation of tumor cells and the accumulation of MPE.With the in-depth study of the tumor microenvironment,the application of local systemic anti-tumor therapy with local intrathoracic application of immune checkpoint inhibitors,immune cells,cytokines,and gene-mediated cytotoxic immunotherapy are able to alleviate the immunosuppressive tumor microenvironment and inhibit the accumulation of MPE.This article aimed to describe the tumor microenvironment in MPE and provide clues for identifying novel therapeutic targets.
作者 谈思含 李为民 田攀文 Tan Sihan;Li Weimin;Tian Panwen(Department of Pulmonary and Critical Care Medicine,State Key Laboratory of Respiratory Health and Multimorbidity,Precision Medicine Key Laboratory of Sichuan Province,West China Hospital,Sichuan University,Chengdu 610041,China)
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2024年第7期668-675,共8页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 国家自然科学基金(82072598)。
  • 相关文献

参考文献4

二级参考文献61

  • 1Hausheer FH, YarbroJW. Diagnosis and treatment of malignant pleural effusion [J]. Semin Oncol, 1985, 12:54-57.
  • 2Skhvatsabaja LV. Secondary malignant lesions of the heart and pericardium in neoplastic disease [J]. Oncology, 1986, 43: 103 - 106.
  • 3Lacy JH, Wieman TJ, Shively EH. Management of malignant ascites [ J]. Surg Gynecol Obstet, 1984, 159 : 397 - 402.
  • 4Pajlia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with souble protein prime cytotoxic T lymphocytes against tumor antigen in vivo[ J]. J Exp Med, 1996, 183:317 - 322.
  • 5Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity [J]. Nat Med, 1995, 1: 1297 - 1302.
  • 6Ratta M, Curti A, Fogli M, et al. Efficient presentation of tumor idiotype to autologous T cells by CD83( + ) dendritic cells derived from highly purified circulating CD14( + ) monocytes in multiple myeloma patients[J]. Exp Hematol, 2000, 28:931 -940.
  • 7Thomas R, Chambers M, Roytar R, et al. Metastatic lesions in the joint associated with acute inflammatory after dendritic cell immunotherapy for metastatic melanoma [J]. Melanoma Res, 1999, 9:474-481.
  • 8Triozzi PL, Khurram R, Aldrich WA, et al. Intraumoral injection of dendritic cells derived in vitro in patients with metastatic cancer[J]. Cancer, 2000, 89 : 2646 - 2654.
  • 9Mackensen A, Krause T, Blum U, et al. Homing of intravenously and intrlymphatically injected human dendritic ceils generated in vitro from CD34^+ hematopoietic progenitor cells [ J ]. Cancer Immunol Immunother, 1999, 48 : 118 - 122.
  • 10Small E J, Fratesi P, Reese DM, et al. Immunotherapy of homonerefractory prostate cancer with antigen-loaded dendritic cells [ J ]. J Clin Oncol, 2000, 18:3879 -3882.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部